CinnarizineThird Party Manufacturing in India

Cinnarizine operates through a dual mechanism as both a calcium channel blocker and a histamine H1 receptor antagonist. As a calcium channel blocker, Cinnarizine inhibits the influx of calcium ions into vestibular sensory cells of the inner ear and vascular smooth muscle cells. In the vestibular apparatus, this calcium antagonism reduces the excitability of hair cells in the ampullae of the semicircular canals, suppressing the abnormal neural signals that generate the sensation of vertigo and nystagmus. On the vascular side, Cinnarizine dilates cerebral and labyrinthine arterioles, improving microcirculation in the inner ear and reducing endolymphatic pressure. This vascular effect is particularly beneficial in conditions such as Menieres disease where compromised blood flow contributes to symptom generation. As an H1 receptor antagonist, Cinnarizine blocks histamine-mediated effects in the vestibular system and the vomiting centre of the medulla oblongata. This antihistaminic action contributes to its efficacy in preventing motion sickness and reducing nausea accompanying vertigo. The molecule also increases erythrocyte deformability and reduces whole blood viscosity, further improving microcirculatory flow. These combined vestibular-suppressant, vasodilatory, rheological, and antihistaminic mechanisms make Cinnarizine a comprehensive therapy for balance disorders of both peripheral and central origin.

Therapeutic Uses

Cinnarizine is prescribed for the treatment of:

• Vestibular Vertigo: First-line therapy for vertigo of peripheral origin including benign paroxysmal positional vertigo, acute vestibular neuronitis, and Menieres disease.
• Motion Sickness: Effective prophylaxis and treatment of nausea, vomiting, and dizziness associated with travel by sea, road, or air.
• Menieres Disease: Reduces frequency and severity of vertiginous episodes, tinnitus, and sensorineural hearing loss.
• Cerebrovascular Disorders: Used as adjunctive therapy in patients with cerebral atherosclerosis, vertebrobasilar insufficiency, and post-stroke rehabilitation.
• Peripheral Circulatory Disorders: Improves symptoms in conditions such as intermittent claudication, Raynauds phenomenon, and diabetic microangiopathy.

Why Manufacturers Choose Cinnarizine

Cinnarizine holds a strong position in the Indian neurology and ENT pharmaceutical segments, driven by the high prevalence of vertigo and balance disorders in the population. Its inclusion in numerous fixed-dose combinations for vertigo further expands its addressable market. Indian manufacturers benefit from a mature and cost-effective API supply chain, with multiple domestic producers ensuring raw material security. The tablet formulation process is well established and does not require specialised manufacturing equipment. Cinnarizine is also frequently co-formulated with other active ingredients such as domperidone, piracetam, and dimenhydrinate, providing opportunities for combination product lines. Given the growing ENT and neurology outpatient volumes across India, Cinnarizine third-party manufacturing continues to offer reliable returns for contract manufacturers serving both the domestic market and export territories in Southeast Asia and Africa.